



ERIK PENSER BANK

Penser Access | Industrial Specialties | Sweden | 8 June 2021

Optifreeze

Eventful Q1

Some Covid impact in Q1

OptiFreeze reported another eventful quarter. The company established an initial commercial agreement for OptiBoost with APH, while merging with ArcAroma and creating a major company in Plant and Food Tech. OptiFreeze has also started production of five machines. However, it is still seeing some impact from Covid-19 such as restricted international travel.

Ready for easing of restrictions

We believe the company is well positioned for eased travel restrictions, both for continued business within OptiBoost and OliveCEPT, and for other existing or upcoming applications. Given the Covid restrictions, we have chosen to make some minor adjustments to our estimates and have postponed our forecasts from 2021 to 2022. In terms of the number of machines sold, our overall forecast for 2021–2022 is unchanged.

Big upside remains

We have downwardly adjusted our estimates somewhat, but believe the long-term potential is unchanged. This means that the adjustments do not impact our assessment of the upside or the valuation. We see a fair value of SEK 136–138 per share and high risk.

Estimate Changes (SEK)			Estimates (SEK)					Risk and Potential			
	Now	Before		20	21e	22e	23e	Motivated value	136.00 - 138.00		
EPS, adj 21e	3.35	3.45	-2.8%	Sales,m	0	140	461	818	Current price	51.10	
EPS, adj 22e	12.06	12.58	-4.1%	Sales Growth	(92.1)%	30.6	43.7%	228.6%	77.5%	Risk level	High
EPS, adj 23e	21.56	21.94	-1.8%	EBITDA, m	(10.4)	79	295	513			
				EBIT, m	(11.9)	62.1	278.4	495.7			
				EPS, adj	(0.98)	3.35	12.06	21.56			
				EPS Growth	21.0%	30.0%	259.8%	78.8%			
				Equity/Share	2.0	26.6	38.6	59.7			
				Dividend	0.00	0.00	0.00	0.00			
				EBIT Marginal	(192.0)%	44.2%	60.4%	60.6%			
				ROE (%)	(27.0)%	0.0%	0.0%	0.0%			
				ROCE	(34.2)%	47.7%	67.7%	66.2%			
				EV/Sales	--x	6.56x	2.00x	1.13x			
				EV/EBITDA	(88.7)x	11.7x	3.1x	1.8x			
				EV/EBIT	(77.5)x	14.8x	3.3x	1.9x			
				P/E, adj	(52.1)x	15.2x	4.2x	2.4x			
				P/Equity	25.5x	1.9x	1.3x	0.9x			
				Dividend yield	0.0%	0.0%	0.0%	0.0%			
				FCF yield	(3.6)%	5.0%	21.7%	0.0%			
				Net Debt/EBITDA	2.1g	(1.4)g	(1.1)g	(1.4)g			

Calendar Events	
Årsstämma	2021-06-28
Q2-report	2021-08-10

Key Figures (mkr)	
Number of Shares	18.3m
Market cap	935
Net Debt	(15)
EV	921
Free Float	92.00%
Avg. No. of Daily Traded Sh.	73.7(k)
Reuters/Bloomberg	OPTI.ST/OPTI:SS

One Year Performance Chart

Analysts	
	hjalmar.jernstrom@penser.se



ERIK PENSER BANK

Penser Access | Industrial Specialties | Sweden | 8 June 2021

Overview

Eventful Q1

Investment Case

OptiFreeze's patented CEPT technology has great market potential for applications in both food and plants. We see it as attractive that the company has a technology with well-documented efficacy, broad industry knowledge in each market, and attractive pricing models with recurring revenues. In 2020, OptiFreeze established agreements with important reference customers APH and Dagab. The additions from ArcAroma now provide exposure to new and attractive markets. Within oliveCEPT, the company has extended an existing evaluation agreement with an olive oil producer in China, and is conducting evaluations in the dairy industry with a leading Swedish dairy. OptiFreeze's management has extensive experience from each sector, and we regard the industry knowledge of individuals like board chairman Ulf Hagman as a significant asset. OptiFreeze and ArcAroma communicated several identified benefits of their merger. OptiFreeze will be able to make use of ArcAroma's organization, which has extensive experience in the market. This provides two benefits. Firstly, OptiFreeze will be able to reduce costs by leveraging ArcAroma's expertise in supply chain management, administration and sales channels. And secondly, ArcAroma's organization creates better conditions for a faster roll-out of machines like OptiBoost. ArcAroma's sales are focused around the olive season, which means the company has a sales force during the summer months that is not fully utilized. This capacity can be used for sales of other systems. For ArcAroma, the merger was motivated by the use of OptiFreeze's knowledge in research and development. This capacity can be employed for further development of the projects that were previously in the separate company ArcAroma.

Company Profile

OptiFreeze is a tech company with a patented technology applied in areas such as preservation that provides properties like extended shelf life and retained aroma for raw materials in the plant and food industry. The technology is called CEPT and has a number of applications at various stages of commercialization. In 2020, OptiFreeze focused a lot on OptiBoost, its system for cut flowers. The main focus of the previously independent ArcAroma was on food, primarily food oils and freshly squeezed juices through its oliveCEPT and juiceCEPT. ArcAroma has also worked with applications in whey protein and oat drinks as well as evaluations in a number of other potential markets.

The companies share the technology that forms the basis of the CEPT system. This uses a process called electroporation, a biological process that leads to increased extraction capacity from the raw material, and higher quality and longer shelf life for the end product. The effects of the process are well documented, and the systems provide efficiency and savings for the company's customers. The process is largely patented, and the company has extensive industry knowledge and insights into fine-tuning systems and processes for different applications. This means that potential competitors would have to handle protracted product development cycles that create large entry barriers in OptiFreeze's markets.

Valuation approach

Our valuation approach is a DCF model for the period 2021-2030. We believe that a DCF valuation best reflects the value of the company's growth potential, while its new growth potential following the merger



ERIK PENSER BANK

Penser Access | Industrial Specialties | Sweden | 8 June 2021

Overview

Eventful Q1

makes it challenging to conduct a valuation against relevant peers. Our model assumes that OptiFreeze will continue its commercial rollout and achieve a CAGR corresponding to 37% for the period 2023–2030. We assume growth beyond the forecast period of 1%, and apply a WACC of 16%. This generates a fair value of SEK 136–138 per share after the merger has been completed.

Target Price

136 - 138 kr

The quarter in detail

The merger of ArcAroma and OptiFreeze has been approved at each shareholder meeting. Following the merger and on the basis of indications from the market, the company increased its sales forecast to 45 machines for the period up to and including 2022. This corresponds to an increase in estimates of 50%. OptiFreeze also established an initial commercial agreement with APH Svenska for the treatment of cut flowers.

After the end of the period, the company proposed a restructuring of the board that makes Ulf Hagman the chairman with an operational role and responsibility for the customer side in the plant applications. Johan Möllerström will become the new CEO with the main responsibility for the day-to-day operations. OptiFreeze has also proposed a name change to OptiCept Technologies, and is planning a list change.

The company talks in its report about a general Covid-19 effect that has impacted several of its segments. It has previously pointed out how travel restrictions affect certain segments such as the work with Syngenta and MM Flowers. Overall, we feel that the pandemic has delayed the company's rollout but believe the impact is only temporary. We believe the company is well positioned to meet the easing of Covid-19 restrictions, such as through announcing the preparatory production of five systems.

Estimate adjustments


Overall, we do not see any long-term effects from Covid-19 during the quarter. We feel that the substantial long-term potential is unchanged, and our estimate adjustments do not entail any changes in the number of machines that we forecast the company to sell in 2021–2022. Below is a summary of our estimate adjustments.

Nya estimat	2021e	2022e	2023e
Omsättning	140	461	818
Tillväxt	N/A	229%	77%
EBIT	62	278	496
Rörelsemarginal	44%	60%	61%
EPS	3	12	21

Tidigare estimat	2021e	2022e	2023e
Omsättning	153	486	853
Tillväxt	N/A	218%	76%
EBIT	64	288	508
Rörelsemarginal	42%	59%	60%
EPS	3	13	22

Förändring i %	2021e	2022e	2023e
Omsättning	-8%	-5%	-4%
EBIT	-3%	-3%	-2%
EPS	-13%	-4%	-2%

Market value EPB est (SEK md)



	2018A	2019A	2020A	2021E	2022E	2023E
Net sales	1	3	0	140	461	818
Other income	1	2	3	16	11	7
Cost of goods sold	0	-4	-1	-38	-136	-267
Gross profit	2	2	2	102	325	551
Cost of sales	-4	-5	-4	-23	-24	-27
Other external expenses	-5	-5	-9	-16	-17	-18
EBITDA	-6	-8	-10	79	295	513
Depreciation/amortisation	-1	-1	-1	-17	-17	-17
Goodwill impairments						
EBIT	-7	-8	-12	62	278	496
Extraordinary items						
Adjusted EBIT	-7	-8	-12	62	278	496
Net financial items	0	0	0	-1	-1	-1
Profit before tax (EBT)	-7	-8	-12	61	278	495
Tax	0	0	0	-13	-57	-101
Minority interest						
Net Income	-7	-8	-12	61	247	395
Net Income (Adjusted)	-7	-8	-12	61	247	395

Balansräkning

	2018A	2019A	2020A	2021E	2022E	2023E
Assets						
Other intangible assets	6	7	12	66	66	66
Tangible fixed assets	2	1	2	11	14	17
Other fixed assets	0	2	1	0	0	0
Goodwill	0	0	0	298	298	298
Total fixed assets	8	10	15	375	378	381
Inventory	2	1	1	0	0	0
Accounts receivable	1	1	1	0	0	0
Cash and cash equivalents	7	14	22	119	336	719
Total current assets	10	15	23	119	336	720
TOTAL ASSETS	18	25	39	495	714	1101
Equity and liabilities						
Equity	15	23	35	487	706	1 093
Total equity	15	23	35	487	706	1 093
Deferred tax liabilities	0	0	0	0	0	0
Non-current liabilities	0	0	2	8	8	8
Current liabilities	3	2	2	0	0	0
Total Equity and Liabilities	18	25	39	495	714	1 101

	2018A	2019A	2020A	2021E	2022E	2023E
EBIT	-7	-8	-12	62	278	496
Changes in working capital	-1	-1	0	7	0	0
Adjustments for items that are not included in cash flow	0	0	1	10	-41	-85
Cash flow from operating activities	-7	-9	-10	79	238	411
Investments	-2	-3	-5	-3	-3	-3
Free Cash Flow	-9	-11	-15	76	235	408
Debt financing and other adjustments	0	18	24	-8	-18	-24
Cash Flow	-9	7	8	68	216	384
Cash end of period	7	14	22	119	336	719

This publication (“the Publication”) has been compiled by Erik Penser Bank (“the Bank”) exclusively for clients of the Bank. The contents are based on information from publicly available sources which have been deemed reliable. No guarantee is extended as to the accuracy and completeness of the contents of the document or the forecasts and recommendations provided therein. The Bank may permit employees of another department or analysed company (“the company”) to read facts or series of facts in order to verify the same. The Bank does not disclose conclusions or assessments included in the Publication in advance. Opinions stated in the Publication are those of the analyst at the time the Publication was prepared and such opinions are subject to change. No assurance is provided that future events will be in accordance with opinions stated in the Publication.

The information in the Publication must not be understood as encouragement or recommendation to enter into transactions. The information does not take into account an individual recipient’s investment knowledge and experience, financial situation, or investment goals. The information thus does not constitute a personal recommendation or investment advice.

The Bank disclaims all liability for direct or indirect loss that may be based upon the Publication. Investments in financial instruments are associated with financial risk. The investment may go up or down in value or become entirely worthless. Past favourable performance of an investment is not a guarantee of future performance.

Fair value and risk

The fair value reflects a value for the share on the day the analysis is published in a range corresponding to approximately 5-10%. The Bank uses several different valuation models to value financial instruments, such as cash flow models, valuation of multiples and breakup value analysis.

The valuation method and the approach for determining the fair value should be apparent in the analysis and may vary from company to company. Significant assumptions used in valuations are based on currently available market data and a scenario for the company’s future development that we consider reasonable. As regards risk, the share is classified on a High-Medium-Low scale based on a number of known parameters relevant to the company. A general guideline for being classified as low risk is that the company has positive cash flow and that no individual factor affects net sales by more than 20%. The corresponding general description of high risk is that the company has not achieved positive cash flow or that an individual factor affects net sales by more than 50%.

The research presented in the Publication was performed in accordance with the terms and conditions of the “Penser Access” service that the Bank performs on behalf of analysed companies. The analysed company remunerates the Bank for the aforementioned service. The fair value and risk classifications are continuously updated. Click here <https://www.penser.se/historiska-analysrekommendationer/> to view the history of investment recommendations issued by the Bank.

General

The Bank’s consent is required to copy or disseminate the Publication in whole or in part. The Publication must not be disseminated or made available to any natural or legal person in the United States of America (other than as provided under Rule 15a–16, Securities Exchange Act of 1934), Canada, or any other country that imposes statutory restrictions on the dissemination and availability of the contents of the material.

The Bank has prepared an Ethics Policy and a Conflicts of Interest Policy. The aim of these policies is to protect against and prevent conflicts between the interests of clients and departments within the Bank. The approach used by the Bank to prevent conflicts of interest includes restrictions on communications (Chinese Walls). The Research Department is physically separated from the Corporate Finance department, which occupies separate premises. The Corporate Finance department is not permitted to participate in the production of a Publication or to express opinions on a Publication. However, there may from time to time exist a client relationship or advisory situation between a company covered in a Publication and a department of the Bank other than the Research Department. The Bank has drawn up internal restrictions concerning when employees are permitted to conduct trades in a financial instrument that is the subject of an Investment Recommendation.

From time to time, the Bank performs assignments for a company that is mentioned in a Publication. The Bank may, for example, be acting as an advisor or issuer agent to the company or as the liquidity guarantor for one of the company’s securities. If such is the case, this has been stated in the Publication. The Bank, its owners, directors, or employees may own shares in companies mentioned in the Publication. All employees of the Bank must report their holdings in securities and must report all transactions. The Bank and its employees comply with guidelines issued by the Swedish Securities Dealers Association concerning employee transactions. The analyst who has prepared Investment Research as referred to in Chapter 11, section 8 of the Swedish Financial Supervisory Authority’s Regulations regarding securities (FFFS 2007:16) and others involved in this work are not permitted to trade on their own account in the covered Financial Instrument or related Financial Instruments in contravention of the applicable recommendation. The Bank’s Compliance Department monitors all employee transactions.

The Bank pays salaries to analysts, which may also consist of a share of the Bank’s profits but which is never linked to the financial performance of another department. Neither the Bank nor the individuals who compiled the Publication have holdings (long or short) in the financial instruments issued by the analysed company that exceed 0.5% of the analysed company’s share capital.

For the company in question, the Bank also conducts research in accordance with the terms of the “Penser Access” paid-for service. Click here <https://epaccess.penser.se/> for more information about this service.

Erik Penser Bank is authorised to conduct securities operations and is under the supervision of the Swedish Financial Supervisory Authority (Finansinspektionen)

Erik Penser Bank (*publ.*)

Apelbergsgatan 27 Box 7405 103 91 STOCKHOLM

tel: +46 8 463 80 00 fax: +46 8 678 80 33 www.penser.se